Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis

References

• Elvin JG, Couston RG. van der Walle CF. Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm. 2013;440:83–9. doi:https://doi.org/10.1016/j.ijpharm.2011.12.039.
   PubMed Web of Science ®Google Scholar
• Tabrizi M, Tseng C-M RL. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81–88. doi:https://doi.org/10.1016/S1359-6446(05)03638-X.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52:83–124.
   PubMed Web of Science ®Google Scholar
• Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14:e1002533. doi:https://doi.org/10.1371/journal.pbio.1002533.
   PubMed Web of Science ®Google Scholar
• Glassman P, Balthasar J. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. J Pharmacokinet Phar. 2016;43:427–46. doi:https://doi.org/10.1007/s10928-016-9482-0.
   PubMed Web of Science ®Google Scholar
• Richter WF, Christianson GJ, Frances N, Grimm H, Proetzel G, Roopenian DC. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. mAbs. 2018;10:803–13. doi:https://doi.org/10.1080/19420862.2018.1458808.
   PubMed Web of Science ®Google Scholar
• Gurbaxani B, Dostalek M, Gardner I. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol. 2013;56:660–74. doi:https://doi.org/10.1016/j.molimm.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68. doi:https://doi.org/10.1002/jps.20178.
   PubMed Web of Science ®Google Scholar
• Hötzel I, Theil F-P-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4:753–60. doi:https://doi.org/10.4161/mabs.22189.
   PubMed Web of Science ®Google Scholar
• Kelly R, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y. Wittrup. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. mAbs. 2016;8:1269–75. doi:https://doi.org/10.1080/19420862.2016.1208330.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010;23:385–92. doi:https://doi.org/10.1093/protein/gzq009.
   PubMedGoogle Scholar
• Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8:e57479. doi:https://doi.org/10.1371/journal.pone.0057479.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368:652–65. doi:https://doi.org/10.1016/j.jmb.2007.02.024.
   PubMed Web of Science ®Google Scholar
• Leipold D, Pharmacokinetic PS. Pharmacodynamic Considerations in the design of therapeutic antibodies. Clin Transl Sci. 2019;12:130–39. doi:https://doi.org/10.1111/cts.12597.
   PubMedGoogle Scholar
• Maas B, Cao Y. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: effects of kon, koff, endosome trafficking, and animal species. Mabs. 2018;10:1322–31. doi:https://doi.org/10.1080/19420862.2018.1506648.
   PubMed Web of Science ®Google Scholar
• Chung S, Lin Y, Nguyen V, Kamen L, Zheng K, Vora B, Song A. Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins. J Immunol Methods. 2018;462:101–05. doi:https://doi.org/10.1016/j.jim.2018.07.004.
   PubMed Web of Science ®Google Scholar
• Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol. 2006;176:346–56. doi:https://doi.org/10.4049/jimmunol.176.1.346.
   PubMed Web of Science ®Google Scholar
• Jensen P, Schoch A, Larraillet V, Hilger M, Schlothauer T, Emrich T, Rand K. A two-pronged binding mechanism of IgG to the neonatal Fc receptor controls complex stability and IgG serum half-life. Mol Cell Proteomics. 2017;16:451–56. doi:https://doi.org/10.1074/mcp.M116.064675.
   PubMed Web of Science ®Google Scholar
• Bumbaca D, Boswell AC, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. Aaps J. 2012;14:554–58. doi:https://doi.org/10.1208/s12248-012-9369-y.
   PubMed Web of Science ®Google Scholar
• Sharma V, Patapoff T, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley R, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A. 2014;111:18601–06. doi:https://doi.org/10.1073/pnas.1421779112.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Lu J, Witcher D, Leung D, Tang Y, Wroblewski V. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. Mabs. 2015;7:1084–93. doi:https://doi.org/10.1080/19420862.2015.1075109.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Croy J, Schirtzinger L, Torgerson S, Breyer M, Wroblewski V. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys. mAbs. 2016;8:969–82. doi:https://doi.org/10.1080/19420862.2016.1178435.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher D, Lu J, Wroblewski V. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. Mabs. 2015;7:483–93. doi:https://doi.org/10.1080/19420862.2015.1016696.
   PubMed Web of Science ®Google Scholar
• Li B, Tesar D, Boswell A, Cahaya H, Wong A, Zhang J, Meng G, Eigenbrot C, Pantua H, Diao J, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. mAbs. 2014;6:1255–64. doi:https://doi.org/10.4161/mabs.29809.
   PubMed Web of Science ®Google Scholar
• Bernfield M, Götte M, Park P, Reizes O, Fitzgerald M, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729–77. doi:https://doi.org/10.1146/annurev.biochem.68.1.729.
   PubMed Web of Science ®Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y-Y, Torrey J, Thomas J, Bobrowicz P, Vásquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26:663–70. doi:https://doi.org/10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• Gurbaxani B, Cruz L, Chintalacharuvu K, Morrison S. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol. 2006;43:1462–73. doi:https://doi.org/10.1016/j.molimm.2005.07.032.
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc National Acad Sci. 2015;112:5997–6002. doi:https://doi.org/10.1073/pnas.1408766112.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Rueger P, Stracke J, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. mAbs. 2013;5:576–86. doi:https://doi.org/10.4161/mabs.24981.
   PubMed Web of Science ®Google Scholar
• Ober R, Radu C, Ghetie V, Ward S. Differences in promiscuity for antibody–fcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13:1551–59. doi:https://doi.org/10.1093/intimm/13.12.1551.
   PubMed Web of Science ®Google Scholar
• Abdiche Y, Yeung Y, Chaparro-Riggers J, Barman I, Strop P, Chin S, Pham A, Bolton G, McDonough D, Lindquist K, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs. 2015;7:331–43. doi:https://doi.org/10.1080/19420862.2015.1008353.
   PubMed Web of Science ®Google Scholar
• Neuber T, Frese K, Jaehrling J, Jäger S, Daubert D, Felderer K, Linnemann M, Höhne A, Kaden S, Kölln J, et al. Characterization and screening of IgG binding to the neonatal Fc receptor. mAbs. 2014;6:928–42. doi:https://doi.org/10.4161/mabs.28744.
   PubMed Web of Science ®Google Scholar
• Borrok J, Wu Y, Beyaz N, Yu X-Q, Oganesyan V, Dall’Acqua W, Tsui P. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Bio Chem. 2015;290:4282–90. doi:https://doi.org/10.1074/jbc.M114.603712.
   PubMed Web of Science ®Google Scholar
• Souders C, Nelson S, Wang Y, Crowley A, Klempner M, Thomas W. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. mAbs. 2015;7:912–21. doi:https://doi.org/10.1080/19420862.2015.1054585.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci USA. 2017;114:944–49. doi:https://doi.org/10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Proetzel G, Wiles M, Roopenian D. Genetically engineered humanized mouse models for preclinical antibody studies. BioDrugs. 2014;28:171–80. doi:https://doi.org/10.1007/s40259-013-0071-0.
   PubMedGoogle Scholar
• Andersen J, Daba M, Berntzen G, Michaelsen T, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Bio Chem. 2010;285:4826–36. doi:https://doi.org/10.1074/jbc.M109.081828.
   PubMed Web of Science ®Google Scholar
• Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods. 2012;375:20–29. doi:https://doi.org/10.1016/j.jim.2011.09.002.
   PubMedGoogle Scholar
• Petkova A, Sproule C, Khabbaz A, Brown P, Meng R. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18:1759–69. doi:https://doi.org/10.1093/intimm/dxl110.
   PubMed Web of Science ®Google Scholar
• Avery L, Wang M, Kavosi M, Joyce A, Kurz J, Fan -Y-Y, Dowty M, Zhang M, Zhang Y, Cheng A, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. mAbs. 2016;8:1–15. doi:https://doi.org/10.1080/19420862.2016.1193660.
   PubMed Web of Science ®Google Scholar